Literature DB >> 17303253

Quantitative demonstration of intrathecal synthesis of high affinity immunoglobulin G in herpes simplex encephalitis using affinity-mediated immunoblotting.

Miles D Chapman1, Edward J Thompson, Paul M Candler, Russell C Dale, Andrew J Church, Gavin Giovannoni.   

Abstract

Three paired serial samples of CSF and serum (from days 8, 13 and 22) were taken from a patient referred to the National Hospital for Neurology and Neurosurgery with what was duly confirmed as having herpes simplex encephalitis using PCR. The samples were investigated using affinity-mediated immunoblotting followed by incubation with sodium thiocyanate. Digitisation of the blots enabled further analysis. We showed that the clones of antigen-specific IgG, which were produced intrathecally, were of higher relative affinity than polyclonal antigen-specific IgG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303253     DOI: 10.1016/j.jneuroim.2007.01.002

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  Diagnostic strategy used to establish etiologies of encephalitis in a prospective cohort of patients in England.

Authors:  H E Ambrose; J Granerod; J P Clewley; N W S Davies; G Keir; R Cunningham; M Zuckerman; K J Mutton; K N Ward; S Ijaz; N S Crowcroft; D W G Brown
Journal:  J Clin Microbiol       Date:  2011-08-24       Impact factor: 5.948

2.  Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Carmine Tamborino; Silva Seraceni; Maria Rosaria Tola; Enrico Granieri; Carlo Contini
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

3.  Serum matrix metalloproteinase-2 levels indicate blood-CSF barrier damage in patients with infectious meningitis.

Authors:  Yuhsaku Kanoh; Tadashi Ohara; Motonari Kanoh; Tohru Akahoshi
Journal:  Inflammation       Date:  2008-01-10       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.